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Abstract
Background: Although currently misclassified in the International Classification of Diseases (ICD) and still not
officially listed as a rare disease, anaphylaxis is a well-known clinical emergency. Anaphylaxis is now one of the
principal headings in the “Allergic and hypersensitivity conditions” section recently compiled for the forthcoming
11th Revision of ICD (ICD-11). We here report the building process used for the pioneering “Anaphylaxis” subsection
of ICD-11 in which we aimed for transparency as recommended in the ICD-11 revision guidelines.
Results: During an online intensive scientific and technical discussions with ICD-11 Topic Advisory Groups and Expert
Working Groups, we drafted a total of 35 proposals for the classification of anaphylaxis. From all the 35 proposals, 77%
were implemented, 20% remain to be implemented, and the others being partially implemented (1.5%) or rejected (1.5%).
Conclusion: For the first time, anaphylaxis is now properly classified and has attained greater visibility within ICD. In
addition to all the benefits expected from the actions we have undertaken in updating the terminology, definitions and
classification of allergic and hypersensitivity conditions for ICD-11, we strongly believe that anaphylaxis should be a public
health priority and that it should therefore be formally added into the list of rare diseases in order to support awareness
and quality clinical management of patients.
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Background
Anaphylaxis as a rare disease: definitions, epidemiology
and unmet needs
Since the term “anaphylaxis” was first coined by Charles
Richet and Paul Portier [1], it has rapidly spread all over
the world and its clinical importance as an emergency
condition is now well accepted. Anaphylaxis is nowadays
recognized as a severe, life-threatening systemic hyper-
sensitivity reaction characterized by rapid onset and the
potential to endanger life through airway, breathing, or
circulatory problems. It is usually, although not always,
associated with skin and mucosal changes [2–4]. This
multi-faceted condition can manifest at any age and any
health professional may be faced by it. In recent years
there has been an increasing number of publications
aimed at heightening awareness of this issue (Fig. 1).
Regional epidemiological data cite anaphylaxis incidence
rates ranging from 1.5 to 7.9 per 100 000 person-years in
European countries [4] and estimated in at 5.1% (95% CI,
3.4 to 6.8%) in the United States [5]. Based on these statis-
tics, anaphylaxis would fit well the definition of a rare dis-
ease, although it is not currently listed in rare diseases
registries [6]. The epidemiological criteria for designating
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a condition a “rare disease” vary depending on the refer-
ence in consideration but, conceptually, rare diseases can
be defined as life-threatening or chronic debilitating disor-
ders which are of low prevalence and typically require
combined efforts to address them. The global epidemio-
logical morbidity [7] and mortality [8] data for anaphylaxis
remain unclear due to the lack of standardized tools for
capturing harmonized and accurate data, particularly in
the International Classification of Diseases, Injuries and
Cause of Death (ICD). This fact has a direct impact on the
awareness it receives for healthcare planning and resource
allocation, quality patient management and public health
policy.
Anaphylaxis in the International Classification of Diseases
The ICD is a global standard diagnostic classification for
mortality and morbidity statistics maintained by the
World Health organization (WHO). Currently the ma-
jority of countries use the tenth revision of ICD (ICD-
10) or adaptations thereof [9]. ICD-10 has inherited a
structure from previous versions of ICD in which topo-
graphic distribution frequently takes precedence over
underlying mechanisms, triggers or any of the concepts
currently used for allergic and hypersensitivity conditions.
As a result, only two terms in ICD-10 for anaphylaxis are
hidden within section T78 of Other and unspecified effects
of external causes under the unsatisfactory title Adverse
effects, not elsewhere classified [10]. The inadequacy of this
classification is a major reason for the under-notification
of anaphylaxis in vital statistics [8].
In development since 2007, ICD-11 is intended not
only to rectify deficiencies in ICD-10 and to incorporate
changes demanded by scientific advances, but also to take
advantage of the revolution in electronic data handling
since the publication of ICD-10 a quarter of a century ago.
ICD-11 may be regarded as a suite of classifications which
is based on a detailed and comprehensive polyhierarchical
web-like Foundation (Fig. 2) in which any single disease
entity may be represented in more than one location.
From this Foundation may be extracted any number of
traditional tabular lists, which differ from the Foundation
in that a single entity may appear in only one loca-
tion (as in ICD-10 and, as in the latter’s proposed re-
placement, the ICD-11 for Mortality and Morbidity
Statistics (ICD-11 MMS)). This will also permit the
construction of a range of specialist classifications in
which the detail contained in the Foundation is
retained but which can link to ICD-11 MMS.
In order to create a more appropriate classification for
allergic and hypersensitivity conditions in ICD-11, a
detailed action plan was coordinated in 2012 based on
scientific evidence for the necessity of change; each step
has been documented by peer-reviewed publications
[7, 8, 11–19]. The continuing close collaboration
between our group and WHO has the backing of the Joint
Allergy Academies, composed by representatives of
American Academy of Allergy Asthma and Immunology
(AAAAI), European Academy of Allergy and Clinical
Immunology (EAACI), World Allergy Organization
(WAO), American College of Allergy Asthma and
Immunology (ACAAI), Asia Pacific Association of Allergy,
Asthma and Clinical Immunology (APAAACI), Latin
American Society of Allergy, Asthma and Immunology
(SLAAI). The main outcome of this process has been the
construction of the Allergic and hypersensitivity conditions
section within the new chapter, Disorders the Immune Sys-
tem, which has been incorporated into ICD-11 [16, 20]
(Fig. 3). The “Anaphylaxis” sub-section is one of 8 main
headings in this new section.
Fig. 1 Annual number of publications retrieved from Pubmed Central® using the search term “anaphylaxis”, (accessed July 2016)
Tanno et al. Orphanet Journal of Rare Diseases  (2017) 12:53 Page 2 of 7
Fig. 3 The current “Anaphylaxis” section of the ICD-11 beta draft platform (July 2016 version)
Fig. 2 Example of ICD-11 online polyhierarchical Foundation framework taken the search for the term “Food-dependent exercise-induced anaphylaxis”
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To further inform the allergy community and to en-
sure that the revision process is transparent as advised
in the ICD-11 revision agenda, we report the building
process we used for the pioneering “Anaphylaxis” sub-
section of ICD-11.
Methods
Building the “Anaphylaxis” subsection of ICD-11
The design of the anaphylaxis subsection was based on
the Allergic and hypersensitivity diseases proposal, which
had been validated by crowd-sourcing and simplified
according to ICD Revision Steering Group (RSG)
guidance. The construction of the new Allergic and
hypersensitivity conditions section of the ICD-11 resulted
by intensive scientific, academic and technical discus-
sions to ensure comparability and consistency. The de-
velopment of the “Anaphylaxis” sub-section involved
strong academic input and extensive consultation and
agreement from the relevant Topic Advisory Groups
(TAGs) and Expert Working Groups (EWGs) (Fig. 4).
The intensive exchange of e-mails and teleconference/
videoconferences started in February 2014 and was the
basis for the submission of proposals into the online
ICD-11 beta draft platform. All the actions of the Allergy
Working Group have so far been undertaken with RSG
guidance.
The innovatory electronic authoring and browsing
platforms developed for the ICD Revision Project en-
abled ICD-11 to be assembled and refined in a sophisti-
cated manner including metadata such as definitions,
synonyms and causal mechanisms for each concept and
support for a complex polyhierarchical structure. One of
the most relevant innovations enables proposals for ad-
ditions or changes to be made online [20]. The system
allows for 4 types of proposal: enhancement of content
attached to entity (adding or revising metadata), addition
of new entity as child of existing entity, deletion of entity
and, for more radical proposals, complex hierarchical
changes (Fig. 5). Each submitted proposal has to be sup-
ported with a rationale and peer-reviewed references,
and requires addition of metadata to a standardized
template, the “content model”, which includes: title,
definition, synonyms, narrower term, exclusions, body
system, body site, signs and symptoms, causal agents
and causal mechanisms [20].
The ICD-11 beta draft platform [20] can be considered
a WHO web-observatory in which the representatives of
RSG and TAGs can monitor the proposal submissions
and comments. Based on these, the RSG members can
approve, partially approve or reject a proposal. Each
proposal is then scrutinized by WHO and, if accepted,
can then be implemented and incorporated into the
current version of ICD-11, following which the change
will be visible in the Browser. A proposal may be rejected
in part or in full with the reasons for the decision provided
by commentaries to the proposal. Alternatively further
clarification may be sought from the proposer.
In order to document the construction process fully,
we analyzed all of the above actions in order to describe
the historic and current status of the Anaphylaxis sub-
section and analyze the reasons for the principal
changes. For this evaluation we considered actions
related exclusively to this sub-section and proposals
related to the patient’s background (e.g. personal history
of anaphylaxis). Some proposals related to the topic were
submitted during the revision process in order to adjust
the higher ICD-11 hierarchy in general (e.g. removal of
all anaphylaxis and allergic or hypersensitivity conditions
from the parent Adverse effects, not elsewhere classified
after the construction of the new section). We did not
include proposals not directly related to the patient,
such as Family history of anaphylaxis.
Results
The “Anaphylaxis” sub-section of ICD-11
Most of the proposals for the construction of the
Anaphylaxis sub-section were submitted to the online
ICD-11 Beta draft platform in the period from February
to March 2015, but the hierarchical structure was
adjusted later following additional comments and
proposals. During this process, we submitted a total of
35 proposals, of which 25 (71.5%) were content en-
hancement proposals or complex hierarchical changes.
Of the 35 proposals, 27 (77%) were implemented, 7
(20%) remain to be implemented (Fig. 6). The only
rejected one was related to the proposal of adding a new
entity (Anaphylaxis classified by clinical severity). Justifi-
cations were provided.
Fig. 4 Harmonizing points of views among specialties for the
construction of the ICD-11 “Anaphylaxis” section (TAG = Topic
Advisory Group)
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As a result of all the previous actions, the new
“Anaphylaxis” sub-section was constructed, with 11 en-
tities classified under 7 main headings: Anaphylaxis due
to allergic reaction to food, Drug-induced anaphylaxis,
Anaphylaxis due to insect venom, Anaphylaxis provoked
by physical factors, Anaphylaxis due to inhaled allergens,
Anaphylaxis due to contact with allergens and Anaphyl-
axis secondary to mast cell disorders.
Discussion
Allergic and hypersensitivity disorders are managed not
only by allergists but also by specialists from a range of
different disciplines. As a consequence, intensive scientific
and technical discussions with TAGs and EWGs were es-
sential for achieving consensus for the new classification,
which will for the first time enable anaphylaxis to be
properly represented within ICD.
Since anaphylaxis has never been addressed by a single
section in the ICD, it was to be expected that most of
the proposals were for content enhancement and
complex hierarchical change. These kinds of proposals,
in general, support the building processes of new struc-
tures. The only partially implemented proposal appeared
as such because the incorrect proposal type (deletion of
entity) was inadvertently selected for removal of the link
to a second parent, which is a hierarchical change. As
explained above, the polyhierarchical structure of the
ICD-11 Foundation enables any given entity to be linked
to more than one parent (Fig. 2).
The only rejected proposal concerned the addition of
“Anaphylaxis classified by clinical severity” as a new
entity. The reason for the rejection was that ICD-11
enables diagnoses to be linked to a range of parameters
by the addition of one or more “extensions” in a process
termed post-coordination. WHO has been promoting
Fig. 5 Types of the proposals and its purposes available in the ICD-11 Beta draft
Fig. 6 Proposals submitted into the ICD-11 beta draft platform (as at July 2016) for the construction of the new “Anaphylaxis” section
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this classification strategy in which a stem entity (e.g.
Anaphylaxis) can be more fully defined by linking it to a
range of different value sets including severity, anatom-
ical location and causal agent [20]. All the proposals that
have yet to be implemented are related to “personal his-
tory of” or to instances where the use of post-coordination
would enable the intended meaning to be captured, such
as severity grade or allergens and triggers.
Some limitations of the current study may have to be
considered. Since the online ICD-11 beta draft is not
final and is updated regularly, the current results may
not be reproduced if reanalyzed in the future with the
same methodology. Although this manuscript presents
some technical aspects of classification and new ICD-11
concepts, its aim is also to serve as an introduction to
ICD-11 for ICD end-users in the allergy community
using anaphylaxis as an example.
The construction of the new section dealing with
anaphylaxis means that the latter will now be recognized
as a clinical condition requiring specific documentation
and management. By allowing all the relevant diagnostic
terms for anaphylaxis to be included in the ICD-11
MMS, WHO has recognized their importance not only
to clinicians but also to epidemiologists, statisticians,
health care planners and other stakeholders. Importantly
the new classification will enable the collection of
more accurate epidemiological data to support quality
management of patients with allergies, better health
care planning and decision-making and public health
measures to reduce the morbidity and mortality
attributable to allergy. Examples are the availability of
adrenaline auto-injectors in all countries for patients
at risk, the provision of resuscitation kits in public
places and the implementation of prevention cam-
paigns in surgical and radiology departments.
The Orphanet, lead by the French National Institution
of Health and Medical Research (INSERM) and the
French Ministry of Health, is responsible for developing
an inventory of rare diseases and a classification sys-
tem which could serve as a template to update Inter-
national terminologies. When the WHO launched the
revision process of the ICD, a rare diseases TAG was
established. So far 5,400 rare diseases listed in the
Orphanet database have an endorsed representation
in the foundation layer of ICD-11 [21], but anaphyl-
axis is not yet into the list.
Conclusion
For the first time, anaphylaxis is now properly classi-
fied and has attained greater visibility within ICD.
Additionally to all the benefits expected by the
actions to update terminology, definitions and classifi-
cation of allergic and hypersensitivity conditions
through the ICD-11 revision, we strongly believe that
anaphylaxis is a public health priority and that in
order to support awareness and quality clinical man-
agement of patients it should therefore be formally
added to the list of rare diseases.
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